3.7508.31% ( -0.340 )
Trading: Nov 16, 12:40:03 (EDT)Valuation
Current Valuation
--P/E
$4.09Stock price
--P/E
Stock price$4.09
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03876114152
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAYRYUSBayer | -37.02x | -- | $61.54B |
BAYZFUSBayer Aktiengesellschaft | -36.93x | -- | $61.38B |
VTRSUSViatris | -39.27x | 97.55% | $23.87B |
ELANUSElanco Animal Health | -91.06x | 164.80% | $13.39B |
ABVXUSAbivax SA | -16.42x | 22.99% | $7.63B |
AXSMUSAxsome Therap | -47.38x | 29.75% | $7.45B |
BLTEUSBelite Bio | -59.66x | 25.00% | $6.62B |
CURLFUSCuraleaf Holdings, Inc. | -291.14x | -- | $6.01B |
VREOFUSVIREO GROWTH INC | -89.78x | -- | $5.82B |
MANEUSVeraDermics | -52.74x | 97.55% | $5.42B |
LQDAUSLiquidia Tech | -54.92x | 90.83% | $5.17B |
DFTXUSDefinium Therapeutics | -13.01x | 41.26% | $4.39B |
TARSUSTarsus Pharmaceuticals | -5.64x | 879.07% | $3.96B |
AMLXUSAmylyx Pharmaceuticals | -23.86x | 0.72% | $3.89B |
ELVNUSEnliven Therapeutics | -31.65x | 3.43% | $3.59B |
BHCUSBausch Health | -3.72x | 511.90% | $3.13B |
XERSUSXeris Biopharma | -468.56x | -- | $3.04B |
MBXUSMBX Biosciences | -18.57x | 49.14% | $2.69B |
RGCUSRegencell Bioscience | -209.17x | -- | $2.45B |
PHVSUSPharvaris BV | -11.25x | 15.70% | $2.34B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
